ArticleThe Journal of infectious diseases2026
Bacterial Meningitis Epidemiology in Burkina Faso and Niger-High-Risk Countries in the Meningitis Belt of Sub-Saharan Africa, 2015-2023.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
backgroundBurkina Faso and Niger experience hyperendemic meningitis. We describe their bacterial meningitis epidemiology during 2015-2023, after meningococcal A and prior to meningococcal ACWYX (Men5CV) conjugate vaccine introductions.
methodsCase-based surveillance included demographics, clinical information, and cerebrospinal fluid (CSF) specimens from suspected meningitis cases. CSF specimens were tested by real-time polymerase chain reaction (rt-PCR) and culture to detect Neisseria meningitidis (Nm), Streptococcus pneumoniae (Sp), or Haemophilus influenzae (Hi). Nm serogroup (A, C, W, Y, X, B, or indeterminate) was established by rt-PCR or slide agglutination. Annual incidences were calculated using country census estimates as population denominators.
resultsDuring 2015-2023, 20 538 suspected cases were reported in Burkina Faso and 18 047 in Niger. In Burkina Faso, 3722 of 16 350 CSF specimens tested were positive; 2357 (64%) were Sp and 512 (14%) Nm serogroup W; Hi and Nm serogroups A, C, X, and indeterminate were also detected (<1%-9% each). In Niger, 4372 of 11 076 CSF specimens tested were positive; 3003 (69%) were Nm serogroup C and 703 (16%) were Sp; Hi and Nm serogroups B, W, X, and indeterminate were also detected (<1%-8% each). Average annual incidences per 100 000 population of Nm, Sp, and Hi were 0.7, 1.6, and 0.2 for Burkina Faso and 4.1, 0.8, and 0.2 for Niger. Children aged 5-9 years in Burkina Faso and 10-14 years in Niger had the highest Nm incidences.
conclusionsNm, Sp, and Hi continue to cause disease in Burkina Faso and Niger. Men5CV could help address the burden of serogroup C, W, and X meningococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.